Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 160 combinations with enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
NL-OMON54909Phase 1Withdrawn
- Sponsor
- Amgen
- Start
- Jul 2020
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of acapatamab, enzalutamide and abiraterone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Amgen. Primary endpoints: Dose-limiting toxicities, Treatment-emergent and treatment-related adverse events and 1 more. Planned start Jul 2020; status: withdrawn.
02
Drugs
acapatamabenzalutamideabiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON54909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54909.